Gelonghui Feb. 5 | Yahong Pharmaceutical (688176.SH) dropped to 5.2 yuan in 20CM, a record low, with a total market value of 2,964 billion yuan. On the evening of February 4, Yahong Pharmaceutical announced that key clinical trial data on the company's product APL-1202 combined with chemotherapy infusion to treat recurrent medium- and high-risk non-muscle-invasive bladder cancer (NMIBC) with second-line chemotherapy perfusion showed that stratification according to current guidelines showed a certain trend of efficacy in event-free survival among high-risk NMIBC patients, but the trial did not reach the main research end point. The company decided to discontinue further development of the joint use of APL-1202 with chemotherapeutic infusion.
A股异动 | 亚虹医药跌停创历史新低 终止APL-1202与化疗联用的开发
A-share changes | Yahong Pharmaceutical fell to a record low and terminated the development of APL-1202 in combination with chemotherapy
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.